Voltar
Errata Acesso aberto Revisado por pares
BIBTEX RIS

Corrigendum to ‘Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q'

2021; Elsevier BV; Volume: 32; Issue: 8 Linguagem: Inglês

10.1016/j.annonc.2021.05.797

ISSN

1569-8041

Autores

Komal Jhaveri, X.V. Wang, Vicky Makker, Shiuh‐Wen Luoh, Edith P. Mitchell, James A. Zwiebel, Elad Sharon, Robert J. Gray, S. Li, Lisa M. McShane, Larry Rubinstein, David R. Patton, P. Mickey Williams, S. R. Hamilton, Barbara A. Conley, Carlos L. Arteaga, Lyndsay N. Harris, P J O'Dwyer, A. P. Chen, Keith T. Flaherty,

Tópico(s)

Esophageal Cancer Research and Treatment

Resumo

The authors regret that Dr Arteaga's disclosures were not complete in the original publication. Dr Arteaga's full disclosure should read as follows: CLA: grant support: Pfizer, Lilly, Radius, PUMA Biotechnology, Bayer, Takeda, Symphogen; honoraria: advisory board/steering committee: Daiichi Sankyo, ABBVIE, Novartis, Lilly, Sanofi, Radius, Taiho Oncology, PUMA Biotechnology, Merck, H3Biomedicine, Symphogen, OrigiMed, Immunomedics, Petra Pharma, G1 Therapeutics, Athenex, Dr Arteaga receives compensation for his role in the Scientific Advisory Board of the Komen Foundation, unrelated to this work; stock options: Provista, Y-TRAP. LNH: patents, royalties, other intellectual property—Philips Healthcare. The authors would like to apologise for any inconvenience caused. Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol QAnnals of OncologyVol. 30Issue 11PreviewThe National Cancer Institute—Molecular Analysis for Therapy Choice (NCI-MATCH) is a national precision medicine study incorporating centralized genomic testing to direct refractory cancer patients to molecularly targeted treatment subprotocols. This treatment subprotocol was designed to screen for potential signals of efficacy of ado-trastuzumab emtansine (T-DM1) in HER2-amplified histologies other than breast and gastroesophageal tumors. Full-Text PDF Open Archive

Referência(s)